Session date: 
Tuesday, January 19, 2016 - 7:30am to 8:30am
Location: 
Wheaton Franciscan--St. Joseph Campus
5000 West Chambers Street
Day Surgery Conference Room
Milwaukee, WI 53210
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Peripheral vascular disease will be addressed through peer discussion and resident/student education pertaining to common and uncommon general and vascular surgery patients.  Special attention will be placed on identifying and treating common causes of morbidity and mortality associated with surgical patients.  Despite advances in medicine morbidity and mortality rates remain a constant challenge for practicing surgeons.  Knowledge of these issues is required to make improvements in our practice and to learn from our colleagues complications helps to improve our future competence and performance.

ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council of Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Wheaton Franciscan Healthcare. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation:
The Medical College of Wisconsin designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
 
Target audience: 
  • Vascular surgeons
  • Surgical residents
  • Medical students
  • Allied Health Professionals
Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Decrease the rate of early thrombosis of fempop grafts.  
  • Better selection of patients who will benefit from endovascular treatment of femoral disease, and incorporation of new technology (drug elution and covered stents) as appropriate.  
  • Increase the rate of fistula creation and maturation.  
Faculty & credentials: 
Planning Committee:
Allan Pasch, MD
Anthony Nelson, MD
Joseph Battista, MD
Kevin Packman, MD 
Presenter:
Kevin Packman, MD
 

All persons in control of content have NO relevant financial relationship to disclose with the exception of the following persons:

NameCompanyRole
Allan Pasch, MDBioConect SystemsResearch
Anthony Nelson, MDStealth TherapeuticsSpeaking/teaching

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

CME Coordinator Contact Information

Name: 
Nancy Becker
Phone number: 
+1 (414) 771-2606